Proficio Capital Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Proficio Capital Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-238	Closed	-$20K	–	319
2019 Q2	$20K	Sell	238 -228	-49%	-$19.5K	0.01%	682
2019 Q1	$41K	Buy	466 +6	+1%	+$556	0.01%	408
2018 Q4	$39K	Sell	460 -31	-6%	-$2.95K	0.02%	357
2018 Q3	$48K	Buy	491 +6	+1%	+$599	0.02%	364
2018 Q2	$46K	Buy	485 +307	+172%	+$26.9K	0.02%	374
2018 Q1	$14K	Sell	178 -38	-18%	-$3.26K	﹤0.01%	691
2017 Q4	$19K	Sell	216 -3	-1%	-$261	0.01%	595
2017 Q3	$20K	Sell	219 -382	-64%	-$33.8K	0.01%	589
2017 Q2	$53K	Buy	601 +50	+9%	+$4.55K	0.02%	369
2017 Q1	$49K	Buy	551 +361	+190%	+$32.1K	0.02%	386
2016 Q4	$16K	Buy	190 +56	+42%	+$4.82K	0.01%	505
2016 Q3	$12K	Buy	134 +104	+347%	+$9.79K	0.01%	540
2016 Q2	$3K	Sell	30 -13	-30%	-$1.1K	﹤0.01%	763
2016 Q1	$4K	Buy	43 +9	+26%	+$732	﹤0.01%	544
2015 Q4	$4K	Buy	+34	New	+$3.55K	﹤0.01%	457

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Proficio Capital Partners's BMRN Position: Q3 2019 in Review

Proficio Capital Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2019, closing a stake of 238 shares — an estimated $20K sold.

Proficio Capital Partners first reported a position in BMRN in Q4 2015 and held it in 15 quarters. The position peaked at $53K in Q2 2017. 437 funds tracked by Wall St. Rank hold BMRN as of Q3 2019.

Proficio Capital Partners reported no remaining BioMarin Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Proficio Capital Partners sold 238 BioMarin Pharmaceuticals shares in Q3 2019, an estimated $20K.
Proficio Capital Partners first reported a position in BioMarin Pharmaceuticals in Q4 2015 and held it in 15 quarters.
Proficio Capital Partners's BioMarin Pharmaceuticals position peaked at $53K in Q2 2017.
437 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2019.

Based on Proficio Capital Partners's 13F filing for Q3 2019, filed 13 Nov 2019.